Glax­o­SmithK­line scraps a LAG3 study, mark­ing an­oth­er fail­ure for the pipeline af­ter a crit­i­cal set­back

An­oth­er gap has ap­peared in Glax­o­SmithK­line’s pipeline.

Fri­day morn­ing the Aus­tralian biotech Im­mutep put out word that Hal Bar­ron’s R&D group at GSK had de­cid­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER